{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T11:02:28Z","timestamp":1785150148950,"version":"3.55.0"},"reference-count":59,"publisher":"Academy of Managed Care Pharmacy","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMCP"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.18553\/jmcp.2026.32.8.911","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T10:41:00Z","timestamp":1785148860000},"page":"911-922","source":"Crossref","is-referenced-by-count":0,"title":["Economic value of ribociclib in early breast cancer in the United States"],"prefix":"10.18553","volume":"32","author":[{"given":"Adam","family":"Brufsky","sequence":"first","affiliation":[{"name":"Department of Medicine, Hematology\/Oncology, University of Pittsburgh School of Medicine, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara M.","family":"Tolaney","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijayakrishna K.","family":"Gadi","sequence":"additional","affiliation":[{"name":"University of Illinois Cancer Center, Chicago"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinglei","family":"Chai","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc., Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Yang","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc., Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiye","family":"Chen","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc., Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxin","family":"Ma","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc., Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng-Yi","family":"Zhou","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc., Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaidyanathan","family":"Ganapathy","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apeksha","family":"Patel","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Sopher","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Alexander","sequence":"additional","affiliation":[{"name":"Novartis Ireland Ltd., Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vamsi","family":"Bollu","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Louis P.","family":"Garrison","sequence":"additional","affiliation":[{"name":"The CHOICE Institute, Department of Pharmacy, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph A.","family":"Sparano","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7818","reference":[{"key":"r1","unstructured":"Surveillance, Epidemiology, and End Results Program. Cancer stat facts: female breast cancer. Accessed April 8, 2025. https:\/\/seer.cancer.gov\/statfacts\/html\/breast.html"},{"key":"r2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz173"},{"key":"r3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.19323"},{"key":"r4","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\n                      \u00ae\n                      ) for Breast Cancer. (Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology [NCCN Guidelines\u00ae] for Breast Cancer V.5.2025. \u00a9 National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed December 9, 2025. To view the most recent complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.) Version 5.2025. Accessed December 9, 2025. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1419"},{"key":"r5","unstructured":"US Centers for Disease Control and Prevention. US cancer statistics female breast cancer stat bite. Accessed January 12, 2025. https:\/\/www.cdc.gov\/united-states-cancer-statistics\/publications\/breast-cancer-stat-bite.html"},{"key":"r6","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34161"},{"key":"r7","unstructured":"KISQALI. Prescribing information. Novartis Pharmaceuticals Corporation; 2024. Accessed December 9, 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/209092Orig1s018lbl.pdf"},{"key":"r8","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105858"},{"key":"r9","unstructured":"Centers for Medicare & Medicaid Services. Medicare Drug Price Negotiation Program: draft guidance, implementation of sections 1191\u20131198 of the Social Security Act for Initial Price Applicability Year 2027. Published May 3, 2024. Accessed October 9, 2024. https:\/\/www.cms.gov\/files\/document\/medicare-drug-price-negotiation-draft-guidance-ipay-2027-and-manufacturer-effectuation-mfp-2026-2027.pdf"},{"key":"r10","unstructured":"National Institute of Health and Care Excellence. Abemaciclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence. Published July 20, 2022. Accessed October 9, 2024. https:\/\/www.nice.org.uk\/guidance\/ta810"},{"key":"r11","unstructured":"National Institute for Health and Care Excellence. Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer. Published March 20, 2019. Accessed October 9, 2024. https:\/\/www.nice.org.uk\/guidance\/ta569"},{"key":"r12","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2020.1794826"},{"key":"r13","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.10.015"},{"key":"r14","unstructured":"National Institute for Health and Care Excellence. Guide to the methods of technology appraisal. Published April 4, 2013. Accessed October 9, 2024. https:\/\/www.nice.org.uk\/process\/pmg9\/chapter\/the-reference-case"},{"key":"r15","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X12454577"},{"key":"r16","unstructured":"ARIMIDEX. Prescribing information. ANI Pharmaceuticals, Inc.; 2024. Accessed October 9, 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/020541s036lbl.pdf"},{"key":"r17","unstructured":"FEMARA. Prescribing information. Novartis Pharmaceuticals Corporation; 2024. Accessed October 9, 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/020726s043lbl.pdf"},{"key":"r18","doi-asserted-by":"publisher","DOI":"10.1177\/17588359231178125"},{"key":"r19","unstructured":"University of Sheffield. National Drug Strategy Unit: Survival Analysis TSD. Accessed March 5, 2024. https:\/\/sheffield.ac.uk\/nice-dsu\/tsds\/survival-analysis"},{"key":"r20","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2025.3700"},{"key":"r21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2014.12.051"},{"key":"r22","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-023-01701-9"},{"key":"r23","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-0305"},{"key":"r24","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-4685"},{"key":"r25","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu456"},{"key":"r26","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70322-X"},{"key":"r27","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21163"},{"key":"r28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.34.1255"},{"key":"r29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2114663"},{"key":"r30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911149"},{"key":"r31","unstructured":"Eli Lilly and Co. Lilly to Present final overall survival analysis from the MONARCH 3 study of Verzenio\n                      \u00ae\n                      (abemaciclib) and additional results from its breast cancer portfolio at the 2023 San Antonio Breast Cancer Symposium. Published December 5, 2023. Accessed April 24, 2024. https:\/\/investor.lilly.com\/node\/49971\/pdf"},{"key":"r32","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.11.011"},{"key":"r33","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyac075"},{"key":"r34","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603326"},{"key":"r35","unstructured":"IBM Watson Health. IBM Micromedex RED BOOK. Accessed March 5, 2024. https:\/\/www.micromedexsolutions.com\/micromedex2\/librarian\/"},{"key":"r36","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-022-12896-0"},{"key":"r37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2024.03.753"},{"key":"r38","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2020.1804871"},{"key":"r39","doi-asserted-by":"publisher","DOI":"10.1017\/S026646231100064X"},{"key":"r40","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.0982"},{"key":"r41","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1109653"},{"key":"r42","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1810527"},{"key":"r43","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0288-z"},{"key":"r44","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11468"},{"key":"r45","unstructured":"Centers for Medicare & Medicaid Services. Physician Fee Schedule search. Accessed October 9, 2024. https:\/\/www.cms.gov\/medicare\/physician-fee-schedule\/search."},{"key":"r46","unstructured":"Agency for Healthcare Research and Quality. Healthcare Cost and Utilization Project. Accessed March 13, 2025. https:\/\/datatools.ahrq.gov\/hcupnet\/"},{"key":"r47","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01913-5"},{"key":"r48","unstructured":"US Bureau of Labor Statistics. Labor force statistics from the current population survey. Accessed December 5, 2024. https:\/\/www.bls.gov\/cps\/cpsaat23.htm"},{"key":"r49","doi-asserted-by":"crossref","unstructured":"Shafrin J, Kim J, Cohen JT, et al.\n                      Valuing the Societal Impact of Medicines and Other Health Technologies: A User Guide to Current Best Practices\n                      . De Gruyter; 2024:29-116.","DOI":"10.1515\/fhep-2024-0014"},{"key":"r50","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djw003"},{"key":"r51","unstructured":"US Food and Drug Administration. Orange Book: approved drug products with therapeutic equivalence evaluations. Accessed October 29, 2025. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/ob\/index.cfm."},{"key":"r52","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.11049"},{"key":"r53","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25347"},{"key":"r54","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5462"},{"issue":"295","key":"r55","first-page":"44","volume":"44","author":"Sundar R","year":"2026","journal-title":"J Clin Oncol"},{"key":"r56","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1712403"},{"key":"r57","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.10.005"},{"key":"r58","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70257-6"},{"key":"r59","unstructured":"Novartis Pharmaceuticals.\n                      Clinical Study Report: Primary Endpoint\/Third Interim Analysis\n                      . Data on file. Novartis Pharmaceuticals; 2023."}],"container-title":["Journal of Managed Care & Specialty Pharmacy"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T10:41:16Z","timestamp":1785148876000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jmcp.org\/doi\/10.18553\/jmcp.2026.32.8.911"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":59,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.18553\/jmcp.2026.32.8.911"],"URL":"https:\/\/doi.org\/10.18553\/jmcp.2026.32.8.911","relation":{},"ISSN":["2376-0540","2376-1032"],"issn-type":[{"value":"2376-0540","type":"print"},{"value":"2376-1032","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]}}}